Orthogem has developed a proprietary process for manufacturing Synthetic Bone Graft (SBG), using approved materials, that maintains a high degree of control over the macroporous and microporous architecture. Orthogem's patented process and know-how ensures that the ceramic grain structure of its bone graft material forms an environment that is particularly favourable to rapid osteocyte in-growth.

Orthogem achieves rapid, high quality bone-ingrowth. The unique characteristics of the Orthogem structure, demonstrated in extensive preclinical studies, (including work at the Centre for Bio-Medical Engineering at the Royal National Orthopaedic Hospital, Stanmore, UK) indicate a bioactive effect resulting in rapid, high quality lamellar bone ingrowth within 6 weeks of implantation, and with the implant site achieving compressive strengths equivalent to the surrounding natural bone.

Click to enlarge image

Orthogem Technology Platform uses conventional Hydroxyapatite (HA) and/or tri Calcium Phosphate (TCP) - both already approved for SBG use - manufactured by a proprietary patented process to achieve its unique multiporous structure. This combination provides Orthogem and its licensees with a fast track to regulatory approval with a new generation SBG that has demonstrated the performance required to challenge conventional autograft.

Orthogem forms a robust and viable implant site. The new bone ingrowth has been demonstrated in extensive preclinical studies to be at least as fast as a recently launched ultra-porous TCP bone graft, but without the high rates of implant degradation and consequent soft tissue invasion demonstrated by other SBGs. Orthogem's design ensures that the SBG resorption rate is carefully matched to the rate of new bone ingrowth, resulting in a robust and viable implant site.

Click to enlarge image

Orthogem is as strong as natural bone by 6 weeks. The high quality bone in-growth results in an implant site that is demonstrably as strong as the surrounding natural bone in less than six weeks. The clinical benefits of a strong implant site are considerable. With a modulus and compressive strength of Orthogem's implant site mimicking that of the surrounding natural bone Orthogem is able to rival autograft without the morbidity and associated costs.

Click to enlarge image

Orthogem is an ideal biologics carrier Further studies show that Orthogem is an ideal slow-release carrier for Bone Morphogenic Proteins (BMP) or other biologics. Orthogem represents an exciting opportunity to reduce BMP concentrations and achieve equivalent or superior results.
	Click to enlarge image

Click to download a one pager of Orthogem's technology.